As Calabrich and colleagues illustrate in their comprehensive review in this issue of ONCOLOGY, there is a seemingly endless array of mechanisms by which the HER2-positive breast cancer cell can escape the control of trastuzumab (Herceptin).
Martine J. Piccart-Gebhart, MD, PhD
Advertisement
Articles by Martine J. Piccart-Gebhart, MD, PhD
Advertisement
Latest Updated Articles
- Trastuzumab Resistance: Bringing Tailored Therapy to the Clinic
Published: October 1st 2008 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
2
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
3
Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment
4
Managing Early Adverse Events With Amivantamab + Lazertinib
5
